Increased expression of V domain Ig suppressor of T Cell activation (VISTA) was found to promote immune resistance following Ipilimumab treatment, which may serve as a new immunotherapeutic target in advanced prostate cancer[128]. The gene discussed is VSIR; the disease is prostate carcinoma.